BioHarvest Sciences Inc. Common Stock (BHST) 10-Year Financial Performance & Capital Metrics

BHST • • Industrial / General

Basic MaterialsAgricultural InputsAgricultural Technology & InnovationBiotech Platforms & Nutraceuticals

AboutBioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.Show more

Revenue $25M +98.8%
EBITDA -$6M +37.1%
Net Income -$13M -2.8%
EPS (Diluted) -0.80 +14.0%
Gross Margin 55.35% +24.5%
EBITDA Margin -22.78% +68.4%
Operating Margin -27.75% +64.7%
Net Margin -51.27% +48.3%
ROE -970.9%
ROIC -70.41% +76.3%
Debt/Equity 10.39
Interest Coverage -3.62 +28.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 158.6%
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗High debt to equity ratio of 10.4x
✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 19.7% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 62.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y158.55%

3Y128.83%

TTM45.88%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.86%

EPS CAGR

10Y-

5Y-

3Y-

TTM44.22%

ROCE

10Y Avg-241.04%

5Y Avg-222.71%

3Y Avg-257.98%

Latest-65.06%

Peer Comparison

Biotech Platforms & Nutraceuticals

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BHSTBioHarvest Sciences Inc. Common Stock	115.6M	5.10	-6.38	98.77%	-36.33%	-153.68%		10.39

Profit & Loss

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	218K	396K	2.1M	5.5M	12.67M	25.19M
Revenue Growth %	-	-	-	-	-	0.82%	4.31%	1.62%	1.3%	0.99%
Cost of Goods Sold+	0	483	0	0	189K	258K	1.43M	4.28M	7.04M	11.25M
COGS % of Revenue	-	-	-	-	0.87%	0.65%	0.68%	0.78%	0.56%	0.45%
Gross Profit+	0	0	0	0	29K	138K	670K	1.22M	5.63M	13.94M
Gross Margin %	-	-	-	-	0.13%	0.35%	0.32%	0.22%	0.44%	0.55%
Gross Profit Growth %	-	-	-	-	-	3.76%	3.86%	0.82%	3.62%	1.48%
Operating Expenses+	127.46K	93.7K	160.8K	4.36M	2.34M	6.3M	9.16M	11.83M	15.6M	20.93M
OpEx % of Revenue	-	-	-	-	10.73%	15.92%	4.36%	2.15%	1.23%	0.83%
Selling, General & Admin	0	0	0	0	920K	4.31M	4.76M	9.35M	12.08M	15.73M
SG&A % of Revenue	-	-	-	-	4.22%	10.89%	2.26%	1.7%	0.95%	0.62%
Research & Development	0	0	0	0	1.35M	1.26M	4.13M	2.31M	3.37M	4.8M
R&D % of Revenue	-	-	-	-	6.17%	3.19%	1.96%	0.42%	0.27%	0.19%
Other Operating Expenses	127.46K	93.7K	160.8K	4.36M	73K	726K	273K	171K	154K	399K
Operating Income+	-127.74K	-93.08K	0	-4.36M	-2.31M	-6.17M	-8.49M	-10.61M	-9.97M	-6.99M
Operating Margin %	-	-	-	-	-10.6%	-15.57%	-4.04%	-1.93%	-0.79%	-0.28%
Operating Income Growth %	-	0.27%	1%	-	0.47%	-1.67%	-0.38%	-0.25%	0.06%	0.3%
EBITDA+	-127.22K	-92.6K	-159.63K	-4.36M	-1.98M	-5.88M	-8.11M	-9.9M	-9.13M	-5.74M
EBITDA Margin %	-	-	-	-	-9.08%	-14.84%	-3.86%	-1.8%	-0.72%	-0.23%
EBITDA Growth %	0.36%	0.27%	-0.72%	-26.28%	0.55%	-1.97%	-0.38%	-0.22%	0.08%	0.37%
D&A (Non-Cash Add-back)	526	484	250	0	331.53K	288K	385.58K	712K	840K	1.25M
EBIT	-127.46K	-93.7K	-159.88K	-4.36M	-2.31M	-6.06M	-9.02M	-9.84M	-10.6M	-10.97M
Net Interest Income+	-2.15K	-6.1K	-3.95K	-780K	-2.25M	-405K	-805K	-1.4M	-1.96M	-1.93M
Interest Income	0	0	0	0	-	131K	0	0	0	0
Interest Expense	2.15K	6.52K	3.95K	780K	2.25M	535.89K	805K	1.4M	1.96M	1.93M
Other Income/Expense	0	0	0	4.36M	-3M	-418K	-1.34M	-624K	-2.6M	-5.92M
Pretax Income+	0	0	0	0	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.9M
Pretax Margin %	-	-	-	-	-24.36%	-16.63%	-4.68%	-2.04%	-0.99%	-0.51%
Income Tax+	0	0	0	0	0	0	0	0	0	8K
Effective Tax Rate %	-	-	-	-	1%	1%	1%	1%	1%	1%
Net Income+	0	0	0	0	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.91M
Net Margin %	-	-	-	-	-24.36%	-16.63%	-4.68%	-2.04%	-0.99%	-0.51%
Net Income Growth %	-	-	-	-	-	-0.24%	-0.49%	-0.14%	-0.12%	-0.03%
Net Income (Continuing)	0	0	0	0	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.56M	0	0	0	0	0
EPS (Diluted)+	-0.44	-0.19	-0.21	-2.34	-1.75	-0.70	-0.70	-0.70	-0.93	-0.80
EPS Growth %	0.39%	0.57%	-0.11%	-10.14%	0.25%	0.6%	0%	0%	-0.33%	0.14%
EPS (Basic)	-0.44	-0.19	-0.21	-2.34	-1.75	-0.70	-0.70	-0.70	-0.93	-0.80
Diluted Shares Outstanding	393.08K	416.06K	578.47K	1.63M	2.95M	9.71M	12.45M	13.05M	13.53M	16.19M
Basic Shares Outstanding	393.08K	416.06K	578.47K	1.63M	2.95M	9.71M	12.45M	13.05M	13.53M	16.19M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	23.86K	3.23K	281.07K	868K	1.24M	2.24M	5.67M	4.32M	9.05M	7.86M
Cash & Short-Term Investments	21.12K	1.85K	278.19K	532K	911K	1.78M	4.12M	1.74M	5.36M	2.39M
Cash Only	21.12K	1.85K	278.19K	532K	911K	1.78M	4.12M	1.74M	5.36M	2.39M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.4K	1.38K	2.88K	0	281K	354K	620K	722K	968K	1.34M
Days Sales Outstanding	-	-	-	-	470.48	326.29	107.66	47.93	27.88	19.45
Inventory	0	0	0	0	51K	100K	928K	1.38M	2.47M	3.65M
Days Inventory Outstanding	-	-	-	-	98.49	141.47	236.54	117.54	127.87	118.63
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	67.79K	80.75K	107.04K	4.76M	779K	3.07M	4.54M	5.07M	5.95M	17.14M
Property, Plant & Equipment	67.79K	80.75K	107.04K	0	651K	2.92M	4.36M	4.91M	5.77M	16.77M
Fixed Asset Turnover	-	-	-	-	0.33x	0.14x	0.48x	1.12x	2.20x	1.50x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	4.76M	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	128K	0	0	0	0	0
Other Non-Current Assets	0	0	0	4.76M	0	144K	179K	163K	179K	371K
Total Assets+	91.66K	83.99K	388.11K	5.63M	2.02M	5.3M	10.21M	9.39M	15M	25M
Asset Turnover	-	-	-	-	0.11x	0.07x	0.21x	0.59x	0.84x	1.01x
Asset Growth %	0.09%	-0.08%	3.62%	13.49%	-0.64%	1.62%	0.92%	-0.08%	0.6%	0.67%
Total Current Liabilities+	71.45K	165.19K	35.63K	27K	26.47M	1.89M	2.92M	11.52M	26.47M	14.26M
Accounts Payable	37.79K	54.85K	35.63K	27K	403K	435K	875K	1.07M	1.78M	3.52M
Days Payables Outstanding	-	41.48K	-	-	778.28	615.41	223.03	91.02	92.2	114.41
Short-Term Debt	31.86K	110.34K	0	0	23.7M	0	0	8.55M	20.53M	3.9M
Deferred Revenue (Current)	0	0	0	0	0	0	0	394K	836K	1000K
Other Current Liabilities	37.79K	47.1K	35.63K	27K	2.15M	353K	1.33M	698K	1.57M	3.66M
Current Ratio	0.33x	0.02x	7.89x	32.15x	0.05x	1.18x	1.94x	0.38x	0.34x	0.55x
Quick Ratio	0.33x	0.02x	7.89x	32.15x	0.05x	1.13x	1.62x	0.26x	0.25x	0.29x
Cash Conversion Cycle	-	-	-	-	-209.31	-147.65	121.17	74.46	63.56	23.67
Total Non-Current Liabilities+	0	0	0	1.88M	2.52M	5.71M	4.43M	3.8M	3.39M	9.41M
Long-Term Debt	0	0	0	0	2.2M	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	320K	2.4M	2.27M	1.67M	1.43M	9.14M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	1.88M	7K	0	340K	123K	1.96M	272K
Total Liabilities	71.45K	165.19K	35.63K	1.91M	28.99M	7.6M	7.35M	15.32M	29.86M	23.67M
Total Debt+	31.86K	110.34K	0	0	26.22M	2.71M	2.66M	10.56M	22.34M	13.82M
Net Debt	10.74K	108.49K	-278.19K	-532K	25.31M	932K	-1.46M	8.82M	16.98M	11.43M
Debt / Equity	1.58x	-	-	-	-	-	0.93x	-	-	10.39x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-59.31x	-14.27x	-	-5.58x	-1.03x	-11.51x	-10.55x	-7.59x	-5.08x	-3.62x
Total Equity+	20.21K	-81.21K	352.48K	3.72M	-26.97M	-2.29M	2.85M	-5.93M	-14.85M	1.33M
Equity Growth %	-0.03%	-5.02%	5.34%	9.55%	-8.26%	0.91%	2.24%	-3.08%	-1.51%	1.09%
Book Value per Share	0.05	-0.20	0.61	2.27	-9.14	-0.24	0.23	-0.45	-1.10	0.08
Total Shareholders' Equity	20.21K	-81.21K	352.48K	3.72M	-30.53M	-2.29M	2.85M	-5.93M	-14.85M	1.33M
Common Stock	0	0	0	0	25K	47.58M	62.56M	65.01M	68.65M	97.75M
Retained Earnings	-337.39K	-409.51K	-598.88K	-5.14M	-41.45M	-49.88M	-59.7M	-70.94M	-83.5M	-96.42M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	14.26K	13.09K	8.39K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.56M	0	0	0	0	0

Cash Flow

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	0	0	0	0	-2.38M	-3.88M	-6.79M	-9.24M	-8.52M	-6.68M
Operating CF Margin %	-	-	-	-	-10.93%	-9.79%	-3.23%	-1.68%	-0.67%	-0.27%
Operating CF Growth %	-	-	-	-	-	-0.63%	-0.75%	-0.36%	0.08%	0.22%
Net Income	-129.61K	-99.8K	-163.83K	-5.13M	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.91M
Depreciation & Amortization	0	0	0	0	324K	288K	385.58K	712K	840K	1.25M
Stock-Based Compensation	0	0	0	0	456K	1.38M	3.37M	0	563K	601K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	129.61K	99.8K	163.83K	5.13M	1.47M	1.27M	-627K	1.59M	1.88M	4.93M
Working Capital Changes	0	0	0	0	674K	-232K	-96K	-308K	755K	-555K
Change in Receivables	2.35K	-99	-1.41K	0	-36K	-73K	-266K	-588K	-22K	-594K
Change in Inventory	0	0	0	0	80K	-49K	-828K	-450K	-1.09M	-1.19M
Change in Payables	0	0	0	0	0	0	0	730K	0	1.04M
Cash from Investing+	0	0	0	0	-34K	-173K	-1.64M	-1.26M	-1.47M	-3.03M
Capital Expenditures	-34.02K	-18.87K	-21.5K	0	-34K	-173K	-1.64M	-1.26M	-1.47M	-2.83M
CapEx % of Revenue	-	-	-	-	0.16%	0.44%	0.78%	0.23%	0.12%	0.11%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	33.95K	18.87K	21.5K	0	0	0	0	0	0	-192K
Cash from Financing+	167.21K	73.28K	435.13K	2.23M	2.12M	4.93M	10.77M	8.14M	13.56M	6.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-12.64K	0	-34.4K	2.23M	-251.72K	0	3.64M	-397K	-131.17K	408K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	0	0	0	0	-2.42M	-4.05M	-8.43M	-10.5M	-10M	-9.52M
FCF Margin %	-	-	-	-	-11.09%	-10.22%	-4.01%	-1.91%	-0.79%	-0.38%
FCF Growth %	-	-	-	-	-	-0.67%	-1.08%	-0.24%	0.05%	0.05%
FCF per Share	-	-	-	-	-0.82	-0.42	-0.68	-0.80	-0.74	-0.59
FCF Conversion (FCF/Net Income)	-	-	-	-	0.45x	0.59x	0.69x	0.82x	0.68x	0.52x
Interest Paid	0	0	533	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-3509.64%	-	-	-970.9%
Return on Invested Capital (ROIC)	-408.59%	-239.77%	-	-200.43%	-227.51%	-	-37460.29%	-371.05%	-297.49%	-70.41%
Gross Margin	-	-	-	-	13.3%	34.85%	31.87%	22.17%	44.45%	55.35%
Net Margin	-	-	-	-	-2435.78%	-1662.63%	-467.51%	-204.37%	-99.15%	-51.27%
Debt / Equity	1.58x	-	-	-	-	-	0.93x	-	-	10.39x
Interest Coverage	-59.31x	-14.27x	-	-5.58x	-1.03x	-11.51x	-10.55x	-7.59x	-5.08x	-3.62x
FCF Conversion	-	-	-	-	0.45x	0.59x	0.69x	0.82x	0.68x	0.52x
Revenue Growth	-	-	-	-	-	81.65%	430.81%	161.56%	130.48%	98.77%

Revenue by Segment

	2024
Total	25.19M
Total Growth	-
Products	24.91M
Products Growth	-

Revenue by Geography

	2024
North America	23.01M
North America Growth	-
Israel	2.18M
Israel Growth	-

Frequently Asked Questions

Growth & Financials

BioHarvest Sciences Inc. Common Stock (BHST) reported $32.7M in revenue for fiscal year 2024.

BioHarvest Sciences Inc. Common Stock (BHST) grew revenue by 98.8% over the past year. This is strong growth.

BioHarvest Sciences Inc. Common Stock (BHST) reported a net loss of $11.9M for fiscal year 2024.

Dividend & Returns

BioHarvest Sciences Inc. Common Stock (BHST) has a return on equity (ROE) of -970.9%. Negative ROE indicates the company is unprofitable.

BioHarvest Sciences Inc. Common Stock (BHST) had negative free cash flow of $10.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BioHarvest Sciences Inc. Common Stock (BHST) 10-Year Financial Performance & Capital Metrics

BHST • • Industrial / General

Basic MaterialsAgricultural InputsAgricultural Technology & InnovationBiotech Platforms & Nutraceuticals

Revenue $25M +98.8%
EBITDA -$6M +37.1%
Net Income -$13M -2.8%
EPS (Diluted) -0.80 +14.0%
Gross Margin 55.35% +24.5%
EBITDA Margin -22.78% +68.4%
Operating Margin -27.75% +64.7%
Net Margin -51.27% +48.3%
ROE -970.9%
ROIC -70.41% +76.3%
Debt/Equity 10.39
Interest Coverage -3.62 +28.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 158.6%
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗High debt to equity ratio of 10.4x
✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 19.7% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 62.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y158.55%

3Y128.83%

TTM45.88%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.86%

EPS CAGR

10Y-

5Y-

3Y-

TTM44.22%

ROCE

10Y Avg-241.04%

5Y Avg-222.71%

3Y Avg-257.98%

Latest-65.06%

Peer Comparison

Biotech Platforms & Nutraceuticals

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BHSTBioHarvest Sciences Inc. Common Stock	115.6M	5.10	-6.38	98.77%	-36.33%	-153.68%		10.39

Profit & Loss

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	218K	396K	2.1M	5.5M	12.67M	25.19M
Revenue Growth %	-	-	-	-	-	0.82%	4.31%	1.62%	1.3%	0.99%
Cost of Goods Sold+	0	483	0	0	189K	258K	1.43M	4.28M	7.04M	11.25M
COGS % of Revenue	-	-	-	-	0.87%	0.65%	0.68%	0.78%	0.56%	0.45%
Gross Profit+	0	0	0	0	29K	138K	670K	1.22M	5.63M	13.94M
Gross Margin %	-	-	-	-	0.13%	0.35%	0.32%	0.22%	0.44%	0.55%
Gross Profit Growth %	-	-	-	-	-	3.76%	3.86%	0.82%	3.62%	1.48%
Operating Expenses+	127.46K	93.7K	160.8K	4.36M	2.34M	6.3M	9.16M	11.83M	15.6M	20.93M
OpEx % of Revenue	-	-	-	-	10.73%	15.92%	4.36%	2.15%	1.23%	0.83%
Selling, General & Admin	0	0	0	0	920K	4.31M	4.76M	9.35M	12.08M	15.73M
SG&A % of Revenue	-	-	-	-	4.22%	10.89%	2.26%	1.7%	0.95%	0.62%
Research & Development	0	0	0	0	1.35M	1.26M	4.13M	2.31M	3.37M	4.8M
R&D % of Revenue	-	-	-	-	6.17%	3.19%	1.96%	0.42%	0.27%	0.19%
Other Operating Expenses	127.46K	93.7K	160.8K	4.36M	73K	726K	273K	171K	154K	399K
Operating Income+	-127.74K	-93.08K	0	-4.36M	-2.31M	-6.17M	-8.49M	-10.61M	-9.97M	-6.99M
Operating Margin %	-	-	-	-	-10.6%	-15.57%	-4.04%	-1.93%	-0.79%	-0.28%
Operating Income Growth %	-	0.27%	1%	-	0.47%	-1.67%	-0.38%	-0.25%	0.06%	0.3%
EBITDA+	-127.22K	-92.6K	-159.63K	-4.36M	-1.98M	-5.88M	-8.11M	-9.9M	-9.13M	-5.74M
EBITDA Margin %	-	-	-	-	-9.08%	-14.84%	-3.86%	-1.8%	-0.72%	-0.23%
EBITDA Growth %	0.36%	0.27%	-0.72%	-26.28%	0.55%	-1.97%	-0.38%	-0.22%	0.08%	0.37%
D&A (Non-Cash Add-back)	526	484	250	0	331.53K	288K	385.58K	712K	840K	1.25M
EBIT	-127.46K	-93.7K	-159.88K	-4.36M	-2.31M	-6.06M	-9.02M	-9.84M	-10.6M	-10.97M
Net Interest Income+	-2.15K	-6.1K	-3.95K	-780K	-2.25M	-405K	-805K	-1.4M	-1.96M	-1.93M
Interest Income	0	0	0	0	-	131K	0	0	0	0
Interest Expense	2.15K	6.52K	3.95K	780K	2.25M	535.89K	805K	1.4M	1.96M	1.93M
Other Income/Expense	0	0	0	4.36M	-3M	-418K	-1.34M	-624K	-2.6M	-5.92M
Pretax Income+	0	0	0	0	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.9M
Pretax Margin %	-	-	-	-	-24.36%	-16.63%	-4.68%	-2.04%	-0.99%	-0.51%
Income Tax+	0	0	0	0	0	0	0	0	0	8K
Effective Tax Rate %	-	-	-	-	1%	1%	1%	1%	1%	1%
Net Income+	0	0	0	0	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.91M
Net Margin %	-	-	-	-	-24.36%	-16.63%	-4.68%	-2.04%	-0.99%	-0.51%
Net Income Growth %	-	-	-	-	-	-0.24%	-0.49%	-0.14%	-0.12%	-0.03%
Net Income (Continuing)	0	0	0	0	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.91M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.56M	0	0	0	0	0
EPS (Diluted)+	-0.44	-0.19	-0.21	-2.34	-1.75	-0.70	-0.70	-0.70	-0.93	-0.80
EPS Growth %	0.39%	0.57%	-0.11%	-10.14%	0.25%	0.6%	0%	0%	-0.33%	0.14%
EPS (Basic)	-0.44	-0.19	-0.21	-2.34	-1.75	-0.70	-0.70	-0.70	-0.93	-0.80
Diluted Shares Outstanding	393.08K	416.06K	578.47K	1.63M	2.95M	9.71M	12.45M	13.05M	13.53M	16.19M
Basic Shares Outstanding	393.08K	416.06K	578.47K	1.63M	2.95M	9.71M	12.45M	13.05M	13.53M	16.19M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	23.86K	3.23K	281.07K	868K	1.24M	2.24M	5.67M	4.32M	9.05M	7.86M
Cash & Short-Term Investments	21.12K	1.85K	278.19K	532K	911K	1.78M	4.12M	1.74M	5.36M	2.39M
Cash Only	21.12K	1.85K	278.19K	532K	911K	1.78M	4.12M	1.74M	5.36M	2.39M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.4K	1.38K	2.88K	0	281K	354K	620K	722K	968K	1.34M
Days Sales Outstanding	-	-	-	-	470.48	326.29	107.66	47.93	27.88	19.45
Inventory	0	0	0	0	51K	100K	928K	1.38M	2.47M	3.65M
Days Inventory Outstanding	-	-	-	-	98.49	141.47	236.54	117.54	127.87	118.63
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	67.79K	80.75K	107.04K	4.76M	779K	3.07M	4.54M	5.07M	5.95M	17.14M
Property, Plant & Equipment	67.79K	80.75K	107.04K	0	651K	2.92M	4.36M	4.91M	5.77M	16.77M
Fixed Asset Turnover	-	-	-	-	0.33x	0.14x	0.48x	1.12x	2.20x	1.50x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	4.76M	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	128K	0	0	0	0	0
Other Non-Current Assets	0	0	0	4.76M	0	144K	179K	163K	179K	371K
Total Assets+	91.66K	83.99K	388.11K	5.63M	2.02M	5.3M	10.21M	9.39M	15M	25M
Asset Turnover	-	-	-	-	0.11x	0.07x	0.21x	0.59x	0.84x	1.01x
Asset Growth %	0.09%	-0.08%	3.62%	13.49%	-0.64%	1.62%	0.92%	-0.08%	0.6%	0.67%
Total Current Liabilities+	71.45K	165.19K	35.63K	27K	26.47M	1.89M	2.92M	11.52M	26.47M	14.26M
Accounts Payable	37.79K	54.85K	35.63K	27K	403K	435K	875K	1.07M	1.78M	3.52M
Days Payables Outstanding	-	41.48K	-	-	778.28	615.41	223.03	91.02	92.2	114.41
Short-Term Debt	31.86K	110.34K	0	0	23.7M	0	0	8.55M	20.53M	3.9M
Deferred Revenue (Current)	0	0	0	0	0	0	0	394K	836K	1000K
Other Current Liabilities	37.79K	47.1K	35.63K	27K	2.15M	353K	1.33M	698K	1.57M	3.66M
Current Ratio	0.33x	0.02x	7.89x	32.15x	0.05x	1.18x	1.94x	0.38x	0.34x	0.55x
Quick Ratio	0.33x	0.02x	7.89x	32.15x	0.05x	1.13x	1.62x	0.26x	0.25x	0.29x
Cash Conversion Cycle	-	-	-	-	-209.31	-147.65	121.17	74.46	63.56	23.67
Total Non-Current Liabilities+	0	0	0	1.88M	2.52M	5.71M	4.43M	3.8M	3.39M	9.41M
Long-Term Debt	0	0	0	0	2.2M	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	320K	2.4M	2.27M	1.67M	1.43M	9.14M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	1.88M	7K	0	340K	123K	1.96M	272K
Total Liabilities	71.45K	165.19K	35.63K	1.91M	28.99M	7.6M	7.35M	15.32M	29.86M	23.67M
Total Debt+	31.86K	110.34K	0	0	26.22M	2.71M	2.66M	10.56M	22.34M	13.82M
Net Debt	10.74K	108.49K	-278.19K	-532K	25.31M	932K	-1.46M	8.82M	16.98M	11.43M
Debt / Equity	1.58x	-	-	-	-	-	0.93x	-	-	10.39x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-59.31x	-14.27x	-	-5.58x	-1.03x	-11.51x	-10.55x	-7.59x	-5.08x	-3.62x
Total Equity+	20.21K	-81.21K	352.48K	3.72M	-26.97M	-2.29M	2.85M	-5.93M	-14.85M	1.33M
Equity Growth %	-0.03%	-5.02%	5.34%	9.55%	-8.26%	0.91%	2.24%	-3.08%	-1.51%	1.09%
Book Value per Share	0.05	-0.20	0.61	2.27	-9.14	-0.24	0.23	-0.45	-1.10	0.08
Total Shareholders' Equity	20.21K	-81.21K	352.48K	3.72M	-30.53M	-2.29M	2.85M	-5.93M	-14.85M	1.33M
Common Stock	0	0	0	0	25K	47.58M	62.56M	65.01M	68.65M	97.75M
Retained Earnings	-337.39K	-409.51K	-598.88K	-5.14M	-41.45M	-49.88M	-59.7M	-70.94M	-83.5M	-96.42M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	14.26K	13.09K	8.39K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	3.56M	0	0	0	0	0

Cash Flow

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	0	0	0	0	-2.38M	-3.88M	-6.79M	-9.24M	-8.52M	-6.68M
Operating CF Margin %	-	-	-	-	-10.93%	-9.79%	-3.23%	-1.68%	-0.67%	-0.27%
Operating CF Growth %	-	-	-	-	-	-0.63%	-0.75%	-0.36%	0.08%	0.22%
Net Income	-129.61K	-99.8K	-163.83K	-5.13M	-5.31M	-6.58M	-9.83M	-11.24M	-12.56M	-12.91M
Depreciation & Amortization	0	0	0	0	324K	288K	385.58K	712K	840K	1.25M
Stock-Based Compensation	0	0	0	0	456K	1.38M	3.37M	0	563K	601K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	129.61K	99.8K	163.83K	5.13M	1.47M	1.27M	-627K	1.59M	1.88M	4.93M
Working Capital Changes	0	0	0	0	674K	-232K	-96K	-308K	755K	-555K
Change in Receivables	2.35K	-99	-1.41K	0	-36K	-73K	-266K	-588K	-22K	-594K
Change in Inventory	0	0	0	0	80K	-49K	-828K	-450K	-1.09M	-1.19M
Change in Payables	0	0	0	0	0	0	0	730K	0	1.04M
Cash from Investing+	0	0	0	0	-34K	-173K	-1.64M	-1.26M	-1.47M	-3.03M
Capital Expenditures	-34.02K	-18.87K	-21.5K	0	-34K	-173K	-1.64M	-1.26M	-1.47M	-2.83M
CapEx % of Revenue	-	-	-	-	0.16%	0.44%	0.78%	0.23%	0.12%	0.11%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	33.95K	18.87K	21.5K	0	0	0	0	0	0	-192K
Cash from Financing+	167.21K	73.28K	435.13K	2.23M	2.12M	4.93M	10.77M	8.14M	13.56M	6.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-12.64K	0	-34.4K	2.23M	-251.72K	0	3.64M	-397K	-131.17K	408K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	0	0	0	0	-2.42M	-4.05M	-8.43M	-10.5M	-10M	-9.52M
FCF Margin %	-	-	-	-	-11.09%	-10.22%	-4.01%	-1.91%	-0.79%	-0.38%
FCF Growth %	-	-	-	-	-	-0.67%	-1.08%	-0.24%	0.05%	0.05%
FCF per Share	-	-	-	-	-0.82	-0.42	-0.68	-0.80	-0.74	-0.59
FCF Conversion (FCF/Net Income)	-	-	-	-	0.45x	0.59x	0.69x	0.82x	0.68x	0.52x
Interest Paid	0	0	533	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-3509.64%	-	-	-970.9%
Return on Invested Capital (ROIC)	-408.59%	-239.77%	-	-200.43%	-227.51%	-	-37460.29%	-371.05%	-297.49%	-70.41%
Gross Margin	-	-	-	-	13.3%	34.85%	31.87%	22.17%	44.45%	55.35%
Net Margin	-	-	-	-	-2435.78%	-1662.63%	-467.51%	-204.37%	-99.15%	-51.27%
Debt / Equity	1.58x	-	-	-	-	-	0.93x	-	-	10.39x
Interest Coverage	-59.31x	-14.27x	-	-5.58x	-1.03x	-11.51x	-10.55x	-7.59x	-5.08x	-3.62x
FCF Conversion	-	-	-	-	0.45x	0.59x	0.69x	0.82x	0.68x	0.52x
Revenue Growth	-	-	-	-	-	81.65%	430.81%	161.56%	130.48%	98.77%

Revenue by Segment

	2024
Total	25.19M
Total Growth	-
Products	24.91M
Products Growth	-

Revenue by Geography

	2024
North America	23.01M
North America Growth	-
Israel	2.18M
Israel Growth	-

Frequently Asked Questions

Growth & Financials

BioHarvest Sciences Inc. Common Stock (BHST) reported $32.7M in revenue for fiscal year 2024.

BioHarvest Sciences Inc. Common Stock (BHST) grew revenue by 98.8% over the past year. This is strong growth.

BioHarvest Sciences Inc. Common Stock (BHST) reported a net loss of $11.9M for fiscal year 2024.

Dividend & Returns

BioHarvest Sciences Inc. Common Stock (BHST) has a return on equity (ROE) of -970.9%. Negative ROE indicates the company is unprofitable.

BioHarvest Sciences Inc. Common Stock (BHST) had negative free cash flow of $10.1M in fiscal year 2024, likely due to heavy capital investments.